Smooth Drug Development July 2025 News Release

Monthly News – July 2025

At Smooth Drug Development, we are excited to share the latest updates and achievements from July 2025:

New Projects

We are pleased to announce significant progress in our collaborations:

• Signed contract for medical writing services for a Phase III clinical trial with Cetirizine, strengthening our portfolio in large-scale therapeutic studies.
• Finalized purchase agreement for multiple generic and branded molecules in collaboration with a key Russian pharmaceutical partner.
• We’ve officially signed a contract to develop medical writing documents for a Phase III clinical trial involving Cetirizine, marking another step forward in our expansion into large-scale therapeutic studies.

Clinical and Scientific Departments News:

Our clinical teams continue to deliver excellent results:

• Phase III Hematology Trial: 8 site closure visits completed in July; final site closure scheduled by 1st August 2025.
• Bioequivalence Obesity Trial: Submitted to MoH on 23rd July 2025.
• BE Isotretinoin Study in Russia: Submission of protocol completed.
• Chinese Biotech Trial in Turkey: Approval letter received from the Republic of Türkiye Ministry of Health.
• Phase I Ophthalmology Trial: Enrollment rate increaseddue to intensive work with sites.
• Women’s Health Phase III Trial: Site selection visits ongoing for Diindolylmethane study.
• Gynecology and Multivitamin Study: Final database clean-up and freezing completed on 24th July 2025

Business Development News:

• Product and partnership discussions are underway across China, Israel, and Turkey, including a strategic focus on blood cancer therapies.